# PHOENIX group - Integrated Healthcare Provider account plan

> PHOENIX group is a Mannheim-based pharmaceutical wholesaler and pharmacy operator in 29 European markets, with EUR 53,113.8 million revenue in 2025/26.

## At a glance

PHOENIX group, based in Mannheim and owned solely by the Merckle family, runs pharmaceutical wholesale, pharmacy retail and services for the pharmaceutical industry in 29 European healthcare markets. It operates 204 logistics sites, is number 1 in pharmaceutical wholesale in 14 European countries and owns over 3,200 pharmacies in 16 countries, over 1,900 of them under the BENU brand. In fiscal 2025/26 (February 2025 to January 2026) revenue was EUR 53,113.8 million (+6.8%), profit before tax EUR 636.5 million (+36.7%) and profit after tax EUR 499.1 million, with 48,375 employees at 31 January 2026. The group is not listed but issues bonds and carries an S&P BB+ rating with a positive outlook.

## Business units

- **Germany** (26.9% of 2025/26 revenue (EUR 14,276.7 million)): The largest single market and the fastest-growing region (+9.0%), with 4,664 employees. PHOENIX bought specialty pharmaceutical maker HAEMATO PHARM GmbH at year-end, launched the KIRA AI voice assistant on gesund.de, and lost its Freiburg distribution centre to a fire in October 2025.
- **Western Europe** (46.5% of 2025/26 revenue (EUR 24,711.3 million)): The largest region by revenue, up 6.7%. The report gives no country breakdown; the McKesson Europe units acquired in 2022/23 in France, Italy, Belgium, Ireland, Portugal and Slovenia are still being integrated into group systems.
- **Eastern Europe** (15.3% of 2025/26 revenue (EUR 8,148.9 million)): Revenue up 5.0%. A new distribution centre in Győr, Hungary, the group's largest construction project, is expected to start operating at the end of 2026.
- **Northern Europe** (11.3% of 2025/26 revenue (EUR 6,002.0 million)): The slowest-growing region (+4.0%). It includes Norway's Apotek 1 pharmacies and Tamro Sweden, which bought the B2B e-commerce pharmacy ApoEx Privat Vård in July 2025.

## Strategic priorities

- **WINGS strategic agenda**: WINGS aims at profitable growth and a stronger market lead through three priorities: operational excellence, customer centricity and entrepreneurship, and digitalisation.
- **LEAN and the PHOENIX Production System**: LEAN, launched in 2023, now runs in 23 countries across distribution centres, pharmacies and administration, with over 20,000 employees involved; IT & Digital and Healthcare Logistics started the roll-out in 2025/26.
- **Data and AI**: A Data Hub centralises wholesale and retail transaction data from every country, and the PHOENIX AI Factory takes AI use cases to implementation in 20 countries, covering working capital, B2B customer service, invoice checks, tenders and dynamic pricing.
- **IT consolidation**: Harmonising merchandise-management systems, integrating the former McKesson Europe units and modernising logistics and finance applications in several countries, plus a Digital Workplace Programme in 24 countries.
- **Own brands, loyalty and e-commerce**: The private-label range grew by 264 SKUs to over 900 SKUs in 21 markets, and a Europe-wide loyalty programme started in Serbia in August 2025 is planned for Norway, Ireland and Slovakia in 2026/27.
- **Carbon neutrality by 2030**: The group targets carbon neutrality in its own operations by 2030 and is preparing for CSRD reporting.

## Latest results

Fiscal 2025/26 (to 31 January 2026) beat the guidance of a moderate profit increase: revenue rose 6.8% to EUR 53,113.8 million, EBITDA 11.2% to EUR 1,251.5 million and profit before tax 36.7% to EUR 636.5 million. Gross margin slipped from 10.00% to 9.85%. Operating cash flow rose to EUR 989.3 million and net debt fell 10.2% to EUR 2,646.7 million, with the equity ratio at 27.0%. For 2026/27 the board expects a slight increase in revenue, profit before tax and the equity ratio, with revenue growth slightly above the European pharma markets, expected to grow about 7.0% in 2026.

## Investments and deals

- **Capex on pharmacies and distribution**: Capital expenditure was EUR 260.8 million in 2025/26, mostly for the pharmacy network, modernising distribution centres, automation and logistics services for the pharmaceutical industry.
- **Acquisitions**: ApoEx Privat Vård (Sweden, July 2025) and HAEMATO PHARM GmbH (Germany, year-end); EUR 78.9 million was spent on acquisitions, and buying pharmacies and wholesalers remains part of the strategy.
- **Győr distribution centre**: A new distribution centre in Hungary, the largest construction project, expected to start operating at the end of 2026.
- **Refinancing**: The syndicated facility was refinanced early in July 2025 and raised by EUR 250 million to EUR 1.5 billion; a EUR 500 million 4.875% bond is due 10 July 2029.

## Challenges and risks

- **Margin pressure**: Gross margin slipped from 10.00% to 9.85% on a higher cost-of-goods ratio, and wholesale earnings depend on terms with customers and suppliers in competitive markets.
- **Healthcare savings and online competition**: Lower purchasing power, government healthcare savings measures and online competitors challenge the traditional pharmacy and wholesale business.
- **Energy and transport costs**: Transport and energy make up about 13% of total costs, so high fuel and energy prices remain a risk.
- **IT outages, cyberattacks and site disruption**: IT outages and cyberattacks are named risks, and the October 2025 fire that destroyed the Freiburg distribution centre forced other German centres to take over deliveries.
- **Supply shortages**: Drug supply shortages were a challenge in the year; the group works with suppliers on out-of-stock transparency and holds additional safety stock.

## What leadership says

> "we have proven our resilience and defended our position as a leading healthcare provider in Europe" — Sven Seidel, CEO (Chairman of the Executive Board), CEO letter, Annual Report 2025/26, May 2026 (translated from German)

> "from e-prescriptions to digital customer services to data-driven logistics solutions" — Sven Seidel, CEO (Chairman of the Executive Board), On digitalisation in every country, PHOENIXprint interview, autumn 2025 (translated from German)

> "take advantage of growth opportunities in Europe wherever they arise" — Dr. Bernd Scheifele, Chairman of the Supervisory Board, Supervisory board report, Annual Report 2025/26 (translated from German)


## Where a supplier can help

- **Automation and warehouse systems**: Capex on modernising distribution centres and automation, plus the new Győr distribution centre, create openings for warehouse automation and logistics technology suppliers.
- **AI and data use cases**: The AI Factory and Data Hub programmes, covering dynamic pricing, B2B customer service automation and invoice checks, fit vendors of AI, data and pricing tools.
- **ERP and IT harmonisation**: Harmonising merchandise-management systems and integrating the former McKesson Europe units point to needs in system integration and migration services.
- **Energy and transport cost reduction**: With transport and energy about 13% of total costs and a 2030 carbon neutrality target, fleet, routing and energy-efficiency suppliers have a direct case.
- **Cybersecurity and business continuity**: Cyberattacks and IT outages are named risks and the Freiburg fire showed the cost of site disruption, which supports resilience and security offers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Geschäftsbericht 2025/2026 (Annual Report 2025/26), PHOENIX group](https://www.lobbyregister.bundestag.de/media/64/c2/806620/PHOENIX-group_Geschaeftsbericht-2025-26.pdf)

Annual report · 2026-05-20

- PHOENIX group (PHOENIX Pharma SE, Mannheim; owned solely by the Merckle family, not listed, bond issuer) is Europe's leader in pharmaceutical wholesale, pharmacy retail and pharma-industry services: 29 countries, 48,375 employees, 204 logistics sites, number 1 in wholesale in 14 countries, over 3,200 own pharmacies in 16 countries (over 1,900 under BENU) and over 18,000 pharmacies in its cooperation programmes.
- Fiscal 2025/26 (to 31 January 2026): total operating performance EUR 66,871.4 million (+9.1%), revenue EUR 53,113.8 million (+6.8%, 6.7% organic), EBITDA EUR 1,251.5 million (+11.2%), profit before tax EUR 636.5 million (+36.7%, well above the "moderate" increase guided), profit after tax EUR 499.1 million.
- Revenue by region: Western Europe 46.5% (EUR 24,711.3 million, +6.7%), Germany 26.9% (EUR 14,276.7 million, +9.0%), Eastern Europe 15.3% (+5.0%), Northern Europe 11.3% (+4.0%); no operating segments are reported.
- Balance sheet strengthened: equity ratio 27.0% (25.2%), net debt down EUR 300.8 million to EUR 2,646.7 million, operating cash flow EUR 989.3 million; S&P BB+ with outlook raised to positive; EUR 1.5 billion syndicated facility refinanced early.
- Strategy WINGS: operational excellence (LEAN in 23 countries, over 20,000 employees involved), customer focus and digitalisation (central Data Hub, GenAI programme, an AI Factory covering 20 countries; AI already used for working capital, B2B customer service, invoice checks, tenders and dynamic pricing).
- Growth levers: own brands (over 900 SKUs in 21 markets, new Optamins supplements), a Europe-wide pharmacy loyalty app, e-commerce, and bolt-on M&A (ApoEx Privat Vård in Sweden, specialty-pharma wholesaler HAEMATO PHARM in Germany); capex EUR 260.8 million, new distribution centre in Győr, Hungary, due end-2026.
- Board change from 1 February 2026: Joachim Sowada (Operations & Logistics) and Wolfgang Wallisch (Commercial & Marketing) replaced Stephen Anderson and Stefan Herfeld; CEO Sven Seidel, CFO Dr. Carsten Sauerland.
- Risks: healthcare cost-cutting, competition on wholesale terms, IT outages and cyberattacks, online competitors, transport and energy at about 13% of total costs, longer payment periods in Southern and Eastern Europe, antitrust exposure.
- Outlook 2026/27: slight revenue increase through organic growth and acquisitions, a slight increase in profit before tax and in the equity ratio; European pharma markets expected to grow about 7.0% in 2026, Germany about 6.4%.

### [Quarterly Statement February to October 2025 (nine months 2025/26)](https://www.phoenixgroup.eu/fileadmin/media/Publications/annual_report/2026/PHOENIX_group_Quarterly_Statement_3-2025.pdf)

Interim report · 2025-12-15

- Latest interim publicly available: first nine months of fiscal 2025/26 (February to October 2025); the fiscal 2026/27 interim reports are on a registration-only investor portal.
- Total operating performance (revenue plus handled volume) rose 9.5% to EUR 49.5 billion (9.2% at constant currency); revenue rose EUR 2.7 billion (7.2%) to EUR 39.4 billion.
- EBITDA rose from EUR 833.6 million to EUR 915.2 million; adjusted for a EUR 12.3 million one-off revaluation gain in the prior-year period, EBITDA was up EUR 93.9 million.
- Profit before tax rose from EUR 394.1 million to EUR 465.6 million; profit after tax EUR 337.3 million (prior year EUR 287.7 million).
- Equity ratio up to 26.5% at 31 October 2025 (25.2% at 31 January 2025); net debt EUR 3,112.6 million, up EUR 165.1 million since 31 January 2025.
- Operating cash flow EUR 231.4 million (prior-year period EUR 75.5 million), helped by a higher result and a smaller increase in trade working capital.
- Forecast for 2025/26: slight revenue increase through organic growth and acquisitions, revenue growth in nearly all markets, a noticeable increase in profit before tax and a slight increase in the equity ratio.

### [A strong network for Europe's health: interview with CEO Sven Seidel (PHOENIXprint, autumn 2025)](https://www.phoenix-gh.at/aktuelles/473-netzwerk-europa-gesundheit)

Executive talk · Sven Seidel, CEO (Chairman of the Executive Board), PHOENIX group · 2025-12-10

- Interview with CEO Sven Seidel from the PHOENIXprint customer magazine (autumn 2025 issue), published in German by PHOENIX Austria; quotes below are translations.
- Seidel positions PHOENIX as Europe's leading healthcare provider, active in 29 countries, with its own pharmacies in 17 of them in addition to pharmaceutical wholesale.
- Common demand drivers across Europe: demographics, rising health awareness and the wish for a better quality of life; digitalisation everywhere, from e-prescriptions to digital customer services and data-driven logistics.
- Operating model: country subsidiaries that know their local markets, with local expertise pooled and used Europe-wide; he presents those synergies as the customer benefit.
- Strategy: the WINGS agenda, formulated more than five years ago, with three priorities: operational excellence, stronger commercial thinking and acting, and the opportunities of digitalisation.
- Growth: PHOENIX will keep taking targeted opportunities to strengthen its position as Europe's leading healthcare provider; the vision is to be the preferred partner for simple and direct access to health products and services in Europe.
- The web page is an excerpt; the full interview is only in the printed magazine.

## Questions about PHOENIX group - Integrated Healthcare Provider

### What does PHOENIX group do?

PHOENIX supplies pharmacies, doctors and medical institutions as a pharmaceutical wholesaler, runs over 3,200 own pharmacies in 16 countries (BENU, Apotek 1, Rowlands, McCabes, Help Net), and provides logistics and marketing services to the pharmaceutical industry in 29 European markets.

### What is PHOENIX group's revenue?

Revenue was EUR 53,113.8 million in fiscal 2025/26 (February 2025 to January 2026), up 6.8%, with profit before tax of EUR 636.5 million.

### How many employees does PHOENIX group have?

48,375 employees at 31 January 2026, the largest workforces being in the UK, Norway, the Netherlands and Germany.

### Who leads PHOENIX group?

Sven Seidel chairs the Executive Board as CEO, and Dr. Bernd Scheifele chairs the Supervisory Board. The Merckle family is the sole owner.

### What is PHOENIX group's strategy?

Its WINGS agenda focuses on operational excellence (LEAN), customer centricity with own brands and a loyalty programme, and digitalisation through the Data Hub and AI Factory, alongside acquisitions of pharmacies and wholesalers.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
